Hyun-Hong Kim

Inhibitory effects of total saponin from Korean red ginseng via vasodilator-stimulated phosphoprotein-Ser 157 phosphorylation on thrombin-induced platelet aggregation

In this study, we have investigated the effects of total saponin from Korean red ginseng (TSKRG) on thrombin-induced platelet aggregation. TSKRG dose-dependently inhibited thrombin-induced platelet aggregation with IC50 value of about 81.1 μg/mL. In addition, TSKRG dose-dependently decreased thrombin-elevated the level of cytosolic-free Ca2+ ([Ca2+]i), one of aggregation-inducing molecules. Of two Ca2+-antagonistic cyclic nucleotides as aggregation-inhibiting molecules, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), TSKRG significantly dose-dependently elevated intracellular level of cAMP, but not cGMP. In addition, TSKRG dose-dependently inhibited thrombin-elevated adenosine triphosphate (ATP) release from platelets. These results suggest that the suppression of [Ca2+]i elevation, and of ATP release by TSKRG are associated with upregulation of cAMP. TSKRG elevated the phosphorylation of vasodilator-stimulated phosphoprotein (VASP)-Ser157, a cAMP-dependent protein kinase (A-kinase) substrate, but not the phosphorylation of VASP-Ser239, a cGMPdependent protein kinase substrate, in thrombin-activated platelets. We demonstrate that TSKRG involves in increase of cAMP level and subsequent elevation of VASP-Ser157 phosphorylation through A-kinase activation to inhibit [Ca2+]i mobilization and ATP release in thrombin-induced platelet aggregation. These results strongly indicate that TSKRG is a beneficial herbal substance elevating cAMP level in thrombin-platelet interaction, which may result in preventing of platelet aggregation-mediated thrombotic diseases.

Cordycepin-Enriched WIB801C from Cordyceps militaris Inhibits Collagen-Induced (Ca 2+ ) i Mobilization via cAMP-Dependent Phosphorylation of Inositol 1, 4, 5-Trisphosphate Receptor in Human Platelets

In this study, we prepared cordycepin-enriched (CE)-WIB801C, a n-butanol extract of Cordyceps militaris-hypha, and investigated the effect of CE-WIB801C on collagen-induced human platelet aggregation. CE-WIB801C dose-dependently inhibited collagen-induced platelet aggregation, and its IC50 value was 175 μg/ml. CE-WIB801C increased cAMP level more than cGMP level, but inhibited collagen-elevated [Ca2+]i mobilization and thromboxane A2 (TXA2) production. cAMP-dependent protein kinase (A-kinase) inhibitor Rp-8-Br-cAMPS increased the CE-WIB801C-downregulated [Ca2+]i level in a dose dependent manner, and strongly inhibited CE-WIB801C-induced inositol 1, 4, 5-trisphosphate receptor (IP3R) phosphorylation. These results suggest that the inhibition of [Ca2+]i mobilization by CE-WIB801C is resulted from the cAMP/A-kinase-dependent phosphorylation of IP3R. CE-WIB801C suppressed TXA2 production, but did not inhibit the activities of cyclooxygenase-1 (COX-1) and TXA2 synthase (TXAS). These results suggest that the inhibition of TXA2 production by WIB801C is not resulted from the direct inhibition of COX-1 and TXAS. In this study, we demonstrate that CE-WIB801C with cAMP-dependent Ca2+-antagonistic antiplatelet effects may have preventive or therapeutic potential for platelet aggregation-mediated diseases, such as thrombosis, myocardial infarction, atherosclerosis, and ischemic cerebrovascular disease.

Effect of Cordycepin-Enriched WIB801C from Cordyceps militaris Suppressing Fibrinogen Binding to Glycoprotein IIb/IIIa

In this study, we investigated the effects of cordycepin-enriched (CE)-WIB801C, a n-butanol extract of Cordyceps militaris-hypha on collagen-stimulated platelet aggregation. CE-WIB801C dose dependently inhibited collagen-induced platelet aggregation, and had a synergistic effect together with cordycepin (W-cordycepin) from CE-WIB801C on the inhibition of collagen-induced platelet aggregation. CE-WIB801C and cordycepin stimulated the phosphorylation of VASP (Ser157) and the dephosphorylation of PI3K and Akt, and inhibited the binding of fibrinogen to glycoprotein IIb/IIIa (αIIb/β3) and the release of ATP and serotonin in collagen-induced platelet aggregation. A-kinase inhibitor Rp-8-Br-cAMPS reduced CE-WIB801C-, and cordycepin-increased VASP (Ser157) phosphorylation, and increased CE-WIB801C-, and cordycepin-inhibited the fibrinogen binding to αIIb/β3. Therefore, we demonstrate that CE-WIB801C-, and cordycepin-inhibited fibrinogen binding to αIIb/β3 are due to stimulation of cAMP-dependent phosphorylation of VASP (Ser157), and inhibition of PI3K/Akt phosphorylation. These results strongly indicate that CE-WIB801C and cordycepin may have preventive or therapeutic potential for platelet aggregation-mediated diseases, such as thrombosis, myocardial infarction, atherosclerosis, and ischemic cerebrovascular disease.

Inhibitory Effects of Water Extract from Rice Bran Due to cAMP-dependent Phosphorylation of VASP (Ser 157 ) on ADP-induced Platelet Aggregation

In this study, we investigated the effect of water extract from rice bran (RB) on ADP (20 μM)-stimulated platelet aggregation. RB dose-dependently inhibited ADP-induced platelet aggregation, and its IC50 value was 224.0 μg/mL, which was increased by adenylate cyclase inhibitor SQ22536 and cAMP-dependent protein kinase (A-kinase) inhibitor Rp-8-Br-cAMPS. RB elevated the phosphorylation of VASP (Ser 157 ) which was also inhibited by SQ22536 and Rp-8-Br-cAMPS. It is thought that RB-elevated cAMP contributed to the phosphorylation of VASP (Ser 157 ) to inhibit ADP-induced platelet aggregation. Therefore, we demonstrate that RB has an antiplatelet effect via cAMP-dependent phosphorylation of VASP (Ser 157 ), and RB may have preventive or therapeutic potential for platelet aggregation-mediated diseases, such as thrombosis, myocardial infarction, atherosclerosis, and ischemic cerebrovascular disease.

Inhibitory Effects of Rice Bran Water Extract Fermented Lactobacillus plantarum due to cAMP-dependent Phosphorylation of VASP (Ser 157 ) on human Platelet Aggregation

In this study, we investigated the effect of rice bran water extract fermented with Lactobacillus plantarum KCCM-12116 (RBLp) on ADP (20 μM)-, collagen (10 μg/mL)-, and thrombin (0.2 U/mL)-stimulated platelet aggregation. RBLp dose-dependently inhibited ADP-, collagen-, and thrombin-induced platelet aggregation, with IC50 values of 501.1, 637.2, and > 2,000 μg/mL, respectively. The platelet aggregation induced by ADP plus RBLp (750 μg/mL) was increased by the adenylate cyclase inhibitor, SQ22536, and the cAMP-dependent protein kinase (A-kinase) inhibitor, Rp-8-Br-cAMPS. Treatment with RBLp increased the phosphorylation of VASP (Ser 157 ), an A-kinase substrate, which was also inhibited by SQ22536 and Rp-8-Br-cAMPS. It is thought that the RBLp-induced increases in cAMP contributed to the phosphorylation of VASP (Ser 157 ), which in turn resulted in an inhibition of ADP-induced platelet aggregation, thereby indicating that RBLp has an antiplatelet effect via cAMP-dependent phosphorylation of VASP (Ser 157 ). Thus, RBLp may have therapeutic potential for the treatment (or prevention) of platelet aggregation-mediated diseases, such as thrombosis, myocardial infarction, atherosclerosis, and ischemic cerebrovascular disease.

Antiplatelet and antithrombotic effects of cordycepin-enriched WIB-801CE from Cordyceps militaris ex vivo, in vivo, and in vitro

BackgroundA species of the fungal genus Cordyceps has been used as a complementary and alternative medicine of traditional Chinese medicine, and its major component cordycepin and cordycepin-enriched WIB-801CE are known to have antiplatelet effects in vitro. However, it is unknown whether they have also endogenous antiplatelet and antithrombotic effects. In this study, to resolve these doubts, we prepared cordycepin-enriched WIB-801CE, an ethanol extract from Cordyceps militaris-hypha, then evaluated its ex vivo, in vivo, and in vitro antiplatelet and antithrombotic effects.MethodsEx vivo effects of WIB-801CE on collagen- and ADP-induced platelet aggregation, serotonin release, thromboxane A2 (TXA2) production and its associated activities of enzymes [cyclooxygenase-1 (COX-1), TXA2 synthase (TXAS)], arachidonic acid (AA) release and its associated phosphorylation of phospholipase Cβ3, phospholipase Cγ2 or cytosolic phospholipase A2, mitogen-activated protein kinase (MAPK) [p38 MAPK, extracellular signal-regulated kinase (ERK)], and blood coagulation time in rats were investigated. In vivo effects of WIB-801CE on collagen plus epinephrine-induced acute pulmonary thromboembolism, and tail bleeding time in mice were also inquired. In vitro effects of WIB-801CE on cytotoxicity, and fibrin clot retraction in human platelets, and nitric oxide (NO) production in RAW264.7 cells or free radical scavenging activity were studied.ResultsCordycepin-enriched WIB-801CE inhibited ex vivo platelet aggregation, TXA2 production, AA release, TXAS activity, serotonin release, and p38 MAPK and ERK2 phosphorylation in collagen- and ADP-activated rat platelets without affecting blood coagulation. Furthermore, WIB-801CE manifested in vivo inhibitory effect on collagen plus epinephrine-induced pulmonary thromboembolism mice model. WIB-801CE inhibited in vitro NO production and fibrin clot retraction, but elevated free radical scavenging activity without affecting cytotoxicity against human platelets.ConclusionWIB-801CE inhibited collagen- and ADP-induced platelet activation and its associated thrombus formation ex vivo and in vivo. These were resulted from down-regulation of TXA2 production and its related AA release and TXAS activity, and p38MAPK and ERK2 activation. These results suggest that WIB-801CE has therapeutic potential to treat platelet activation-mediated thrombotic diseases in vivo.

Water Extract from Rice Bran Fermented with Lactobacillus plantarum Hong Inhibits Thromboxane A2 Production Associated Microsomal Enzyme Activity in Human Platelets

In this study, we investigated the effect of rice bran water extract fermented with Lactobacillus plantarum Hong (RBLw), on activities of cyclooxygenase-1 (COX-1) and thromboxane A₂ synthase (TXAS), thromboxane A₂ (TXA₂) production associated microsomal enzymes and evaluated its the antiplatelet effect. RBLw, containing 13.5 mg of ferulic acid, dose-dependently inhibited ADP-induced platelet aggregation, and inhibited the production of TXA₂, an aggregation molecule. In addition, RBLw directly inhibited COX-1 activity in a dose-dependent manner, but not TXAS activity in platelet microsomal fraction having cytochrome c reductase (an endoplasmic reticulum marker enzyme) activity and expressing COX-1 (72 kDa) and TXAS (60.5 kDa) proteins. These results suggest that RBLw selectively inhibited the activity of COX-1 rather than TXAS to attenuate TXA₂ production in ADP-activated platelets. Thus, we demonstrate that RBLw might have direct COX-1 antagonistic function for platelet aggregation-mediated diseases, such as thrombosis, myocardial infarction, atherosclerosis, and ischemic cerebrovascular disease.

Antiplatelet Effects of Cordycepin-Enriched WIB-801CE from Cordyceps militaris: Involvement of Thromboxane A2, Serotonin, Cyclooxygenase-1, Thromboxane A2 Synthase, Cytosolic Phospholipase A2

A species of the fungal genus Cordyceps has been used as an ingredient of traditional Chinese medicine. In this study, we prepared cordycepin-enriched WIB-801CE, an ethanol extract from culture solution of Cordyceps militaris-hypha, and evaluated its antiplatelet effects on human platelet aggregation. WIB-801CE dose-dependently inhibited ADP-, collagen-, and thrombin-induced platelet aggregation. These antiplatelet effects by WIB-801CE were associated with the attenuation of thromboxane A₂ (TXA₂) production and serotonin release by ADP, collagen, and thrombin. The inhibition of TXA₂ production by WIB-801CE was due to the inhibition of cyclooxygenase-1, TXA₂ synthase, and cytosolic phospholipase A₂ activity. Therefore, these data suggest that WIB-801CE may be a beneficial component against protection from platelet aggregation-mediated thrombotic disease.

Ischaemic colitis mimicking ascending colon cancer

downloads/reports/Post_discharge_ events_092811.pdf 28 Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996; 124: 884–90. 29 Tierney WM. Improving clinical decisions and outcomes with information: a review. Int J Med Inform 2001; 62: 1–9. 30 Tierney WM, Achieng M, Baker E, Bell A, Biondich P, Braitstein P, Kayiwa D et al. Experience implementing electronic health records in three East African countries. Stud Health Technol Inform 2010; 160(Pt 1): 371–5. 31 Tierney WM, Miller ME, Overhage JM, McDonald CJ. Physician inpatient order writing on microcomputer workstations. Effects on resource utilization. JAMA 1993; 269: 379–83. 32 Gearon CJ. Perspectives on the future of personal health records. 2007 [cited 2011 Sep 11]. Available from URL: http://www.chcf.org/~/media/ MEDIA%20LIBRARY%20Files/PDF/P/ PDF%20PHRPerspectives.pdf 33 Andrews G, Cuijpers P, Craske MG, McEvoy P, Titov N. Computer therapy for the anxiety and depressive disorders is effective, acceptable and practical health care: a meta-analysis. PLoS ONE 2010; 5: e13196. 34 Krist AH, Woolf SH. A vision for patient-centered health information systems. JAMA 2011; 305: 300–1. 35 Ammenwerth E et al. Impact of CPOE on mortality rates – contradictory findings, important messages. Methods Inf Med 2006; 45: 586–93. 36 Hripcsak G, Cimino JJ, Johnson SB, Clayton PD. The Columbia-Presbyterian Medical Center decision-support system as a model for implementing the Arden Syntax. Proc Annu Symp Comput Appl Med Care 1991: 248–52. 37 Tierney WM, Martin DK, Hui SL, McDonald CJ. Using clinical data to predict abnormal serum electrolytes and blood cell profiles. J Gen Intern Med 1989; 4: 375–83. 38 Tierney WM, Overgage JM, Takesue BY, Harris LE, Murray MD, Vargo DL et al. Computerizing guidelines to improve care and patient outcomes: the example of heart failure. J Am Med Inform Assoc 1995; 2: 316–22. 39 MacDonald CJ, Tierney WM, Overhage JM, Martin DK, Smith B, Wodniak C et al. The Regenstrief Medical Record System – experience with MD order entry and community-wide extensions. Proc Annu Symp Comput Appl Med Care 1994; 1059. 40 Gardner RM, Pryor TA, Warner HR. The HELP hospital information system: update 1998. Int J Med Inform 1999; 54: 169–82. 41 Slack WV, Bleich HL. The CCC system in two teaching hospitals: a progress report. Int J Med Inform 1999; 54: 183–96. 42 Teich JM, Glaser JP, Beckley RF, Aranow M, Bates DW, Kuperman GJ et al. The Brigham integrated computing system (BICS): advanced clinical systems in an academic hospital environment. Int J Med Inform 1999; 54: 197–208. 43 Borst F, Appel R, Baud R, Ligier Y, Scherrer JR. Happy birthday DIOGENE: a hospital information system born 20 years ago. Int J Med Inform 1999; 54: 157–67. 44 Berwick DM. Continuous improvement as an ideal in health care. N Engl J Med 1989; 320: 53–6. 45 McDonald CJ, Overhage JM, Tierney WM, Dexter PR, Martin DK, Suico JG et al. The Regenstrief Medical Record System: a quarter century experience. Int J Med Inform 1999; 54: 225–53. 46 Niazkhani Z, Pirnejad H, Berg M, Aarts J. The impact of computerized provider order entry systems on inpatient clinical workflow: a literature review. J Am Med Inform Assoc 2009; 16: 539–49. 47 Chassin MR. Explaining geographic variations. The enthusiasm hypothesis. Med Care 1993; 31(5 Suppl): YS37–44. 48 Eddy DM. Variations in physician practice: the role of uncertainty. Health Aff (Millwood) 1984; 3: 74–89.

Delayed isolated gallbladder rupture after blunt abdominal trauma

A 49-year-old man presented to our emergency department because of lower back pain and paraplegia after a drain pipe had rolled onto him from 20 m above. His vital signs were stable and physical examination revealed abdominal bruising and distension with tenderness, and paraplegia. Laboratory tests showed elevated myoglobin (2250 mg/L) with leukocytosis (19.3 ¥ 10 cells/L), but his aspartate and alanine transaminase and bilirubin levels were normal. Initial abdominal computed tomography (CT) showed multiple vertebral fractures (Fig. 1a) and a haematoma near the third lumbar vertebra (Fig. 1b) with a normal gallbladder (Fig. 1c). On the 20th day after admission, abrupt abdominal distension was noted, and hypoxaemia, fever and shock developed. Follow-up abdominal CT showed a perihepatic fluid collection and loss of continuity of the gallbladder wall suggesting gallbladder perforation (Fig. 1d,e). Diagnostic paracentesis yielded dark bile-coloured fluid. He recovered from shock with intravenous antibiotic treatment and percutaneous drainage, and open cholecystectomy was performed. Injuries to the gallbladder are found in about only 2% of patients with blunt abdominal trauma, and delayed isolated gallbladder rupture is very much rarer. Depending on its anatomical location, isolated gallbladder